ArticleClinical, cosmetic and investigational dermatology2026
Abrocitinib Treatment of Atopic Dermatitis or Eczema in Patients with Coexistent or Prior Psoriasis: Three Cases with Literature Review.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize clinical outcomes of abrocitinib in patients with coexistent psoriasis and atopic dermatitis (AD)/eczema and to synthesize published case-level evidence on Janus kinase (JAK) inhibitors and other biologic strategies for this overlap phenotype. Patients and Methods: We retrospectively reviewed three adults with psoriasis and concurrent eczema/AD-like dermatitis treated with abrocitinib, with outcomes assessed using PASI, SCORAD/IGA, and PP-NRS. A structured search of MEDLINE, Embase, and Web of Science (inception to 31 December 2025) identified eligible reports describing clinically diagnosed psoriasis-eczema/AD overlap treated with JAK inhibitors or biologic agents, with independent screening and de-duplication. Results: Two patients receiving abrocitinib 100 mg/day achieved marked improvement, and one patient refractory to upadacitinib 30 mg/day improved after switching to abrocitinib 200 mg/day; no treatment-related adverse events were observed, and one patient had no recurrence during >4 months of follow-up. In the literature synthesis, 16 JAK inhibitor-treated cases (abrocitinib, upadacitinib, baricitinib) showed consistent clinical benefit, with PASI decreasing from 9-25.9 to 0-3.2 and SCORAD/EASI decreasing from 24.6-71.1 to 0-30.4, and no adverse events reported. Nine cases treated with other biologics also improved (PASI 9.1-35 to 3-7.2; SCORAD/EASI 19.4-59 to 0-9.4), with conjunctivitis reported in one dual-biologic case. Conclusion: Systemic JAK inhibition may offer an integrated option for psoriasis with coexisting eczema/AD, enabling concurrent lesion and symptom control with favorable short-term tolerability. Larger prospective studies with standardized diagnostic confirmation and harmonized outcome reporting are required to clarify long-term safety, durability, and optimal positioning versus biologic regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.